Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
阿利克松與阿斯利康罕見病宣佈與泛加拿大藥品聯盟達成協議，以在治療患有症狀性、不可手術切除的神經纖維瘤類型1的小兒患者中使用科塞魯戈。
Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Alexion、阿斯利康罕見病宣佈與泛加拿大製藥聯盟就Koselugo達成協議，用於治療患有症狀、無法手術的叢狀神經纖維瘤的1型神經纖維瘤兒科患者
資訊熱榜
更新時間